Earnings summaries and quarterly performance for Oric Pharmaceuticals.
Executive leadership at Oric Pharmaceuticals.
Board of directors at Oric Pharmaceuticals.
Research analysts who have asked questions during Oric Pharmaceuticals earnings calls.
AR
Anupam Rama
JPMorgan Chase & Co.
1 question for ORIC
Also covers: APLS, BBIO, BOLD +16 more
CK
Colleen Kusy
Robert W. Baird & Co.
1 question for ORIC
Also covers: APLS, BPMC, CHRS +5 more
KD
Kevin DeGeeter
Ladenburg Thalmann & Co. Inc.
1 question for ORIC
Also covers: IDXG, NVCR, RVMD +2 more
MR
Maury Raycroft
Jefferies
1 question for ORIC
Also covers: ABEO, ALNY, ARWR +11 more
Michael Schmidt
Guggenheim Securities
1 question for ORIC
Also covers: ADAP, ADCT, ARVN +19 more
YN
Yigal Nochomovitz
Citigroup Inc.
1 question for ORIC
Also covers: ALDX, APLS, ARCT +22 more
Recent press releases and 8-K filings for ORIC.
ORIC Pharmaceuticals Provides Pipeline Update at JPMorgan Healthcare Conference
ORIC
New Projects/Investments
Guidance Update
- ORIC Pharmaceuticals is advancing two late-stage oncology assets: Rinsey-Metastat for prostate cancer and Enosertinib for lung cancer.
- The company has a cash runway into the second half of 2028, which extends beyond the anticipated Phase 3 data readout for Rinsey-Metastat in the second half of 2027.
- The first Phase 3 study for Rinsey-Metastat is expected to initiate in the first half of 2026, with dose optimization data anticipated in Q1 2026. This drug has shown a differentiated safety profile compared to its main competitor.
- Enosertinib has demonstrated 100% intracranial ORRs in patients with measurable disease, highlighting its brain-penetrant capabilities, with substantial new data expected in the second half of 2026.
4 days ago
ORIC Pharmaceuticals Updates on Late-Stage Oncology Pipeline and Financial Runway at J.P. Morgan Healthcare Conference
ORIC
New Projects/Investments
Guidance Update
- ORIC Pharmaceuticals is advancing two late-stage oncology assets: rinzimetostat for prostate cancer and enozertinib for lung cancer.
- Rinzimetostat (prostate cancer) has shown a differentiated safety profile and favorable PSA response rates compared to competitors, with a Phase III data readout anticipated in H2 2027.
- Enozertinib (lung cancer), a brain-penetrant TKI, demonstrated 100% intracranial objective response rates (ORRs) in patients with measurable disease, addressing a significant unmet need in EGFR exon 20 and PACC mutations.
- The company plans to initiate its first Phase III study for rinzimetostat in H1 2026 and expects to report dose optimization data in Q1 2026.
- ORIC Pharmaceuticals maintains a cash runway into H2 2028, extending beyond the first Phase III data readout for rinzimetostat.
4 days ago
ORIC Pharmaceuticals Provides Pipeline Update and Financial Runway at JPMorgan Healthcare Conference
ORIC
New Projects/Investments
Guidance Update
- ORIC Pharmaceuticals presented its late-stage pipeline, featuring Rinsey-Metastat for prostate cancer and Enosertinib for lung cancer, at the 44th Annual JPMorgan Healthcare Conference.
- The company has a cash runway into the second half of 2028, which extends beyond the expected second half of 2027 Phase 3 data readout for Rinsey-Metastat.
- ORIC anticipates initiating its first Phase 3 study for Rinsey-Metastat in the first half of 2026, with dose optimization data expected in Q1 2026.
- Enosertinib, a brain-penetrant TKI for lung cancer, showed 100% intracranial objective response rates (ORRs) in patients with measurable disease.
- ORIC notes it is approximately 18 to 24 months behind Pfizer in the prostate cancer PRC2 inhibitor market, as Pfizer's competitor is expected to have its first Phase 3 readout in 2026.
4 days ago
ORIC Pharmaceuticals Announces Positive Enozertinib Phase 1b Results and Future Development Plans
ORIC
New Projects/Investments
Guidance Update
- Enozertinib, ORIC's drug candidate, demonstrated a potential best-in-class profile in EGFR-mutated NSCLC, achieving 67% Objective Response Rate (ORR) in 1L EGFR exon 20 and 80% ORR in 1L EGFR PACC, alongside 100% intracranial ORR in both 1L populations.
- The drug exhibited a competitive safety profile with manageable on-target toxicity and a low rate of discontinuations, leading to the selection of 80 mg once-daily as the recommended dose for potential Phase 3 development.
- Enozertinib is pursuing a significant commercial opportunity, estimated at ~$3.0 to $3.5 billion in the US annually, by addressing approximately 9,000 patients with NSCLC who currently lack approved CNS-active agents.
- Enrollment and follow-up for 1L EGFR exon 20 and 1L EGFR PACC are ongoing, with the next update anticipated in mid-2026, prior to the potential initiation of Phase 3 trial(s).
- ORIC Pharmaceuticals reported $413 million in cash and investments as of September 30, 2025, which is expected to fund the company into 2H 2028, covering funding through primary endpoint readouts from its first Phase 3 trials for ORIC-944 and enozertinib.
Dec 8, 2025, 11:02 AM
ORIC Presents Positive Clinical Data and Development Plans for ORIC-114
ORIC
New Projects/Investments
- ORIC-114, an EGFR inhibitor for non-small cell lung cancer, has demonstrated highly competitive response rates in both pre-treated and front-line EGFR exon 20 and EGFR PACC mutations.
- The drug exhibits profound CNS activity, critical due to the high prevalence of brain metastases, and a lack of significant off-target toxicities.
- 80 milligrams once daily has been selected as the preferred dose for future development, with the next planned update in mid-2026 ahead of potential Phase 3 registrational trials.
- Early data from the first-line EGFR PACC cohort showed an 80% Overall Response Rate (ORR) in 10 patients, and a 100% intracranial ORR in patients with measurable CNS disease.
- The target populations represent a blockbuster opportunity in the U.S. alone, with an estimated commercial opportunity of $3-$3.5 billion for NSCLC.
Dec 7, 2025, 1:00 AM
ORIC Provides Update on ORIC-114 Clinical Trial Results and Future Development
ORIC
Product Launch
New Projects/Investments
- ORIC-114 demonstrated strong efficacy in its global Phase 1b trial for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 and PACC mutations, including a confirmed objective response rate (ORR) of 60% and a disease control rate (DCR) of 93% in efficacy-evaluable first-line EGFR exon 20 patients (effectively 80 mg dose).
- A key differentiator is ORIC-114's profound brain penetrance, achieving an intracranial ORR of 100% for patients with measurable brain metastases in both first-line EGFR exon 20 and first-line EGFR PACC populations, including those with active, untreated disease.
- The 80 milligrams once daily dose has been selected as the preferred dose for future development due to its manageable safety profile, characterized by predominantly grade one or two treatment-related adverse events, a low rate of discontinuations, and no significant off-target toxicities.
- ORIC plans to continue enrollment and long-term durability follow-up in frontline EGFR exon 20 and EGFR PACC populations, with the next update anticipated in mid-2026 ahead of potential Phase 3 registrational trials.
Dec 7, 2025, 1:00 AM
ORIC Pharmaceuticals Presents Enozertinib Data at ESMO Asia Congress 2025
ORIC
New Projects/Investments
- ORIC Pharmaceuticals presented Phase 1b trial data for enozertinib (ORIC-114) in previously treated NSCLC patients with HER2 exon 20 mutations at the ESMO Asia Congress 2025.
- The trial demonstrated a 35% Objective Response Rate (ORR) (26% confirmed ORR) and 100% Disease Control Rate (DCR) in the 80 mg cohort, including patients with active brain metastases.
- Enozertinib was well tolerated with mostly Grade 1 or 2 treatment-related adverse events and a low discontinuation rate of only 2 patients due to TRAEs.
- Enrollment for HER2 exon 20 patients has been completed, and no further development is planned for enozertinib in this specific patient population.
- Based on data from EGFR exon 20 and EGFR atypical mutations, 80 mg QD oral enozertinib has been selected as the dose for potential Phase 3 development, with the next update expected in mid-2026 for 1L NSCLC patients with specific EGFR mutations.
Dec 5, 2025, 6:00 AM
ORIC Pharmaceuticals Presents Positive Enozertinib Data at ESMO Asia Congress 2025
ORIC
New Projects/Investments
- Enozertinib (ORIC-114) demonstrated strong preliminary systemic activity with an 80% Objective Response Rate (ORR) and 100% intracranial ORR in 1L NSCLC patients with EGFR PACC mutations.
- The drug achieved a 36% ORR in median 3L EGFR PACC patients, exceeding competitor benchmarks.
- Enozertinib exhibited a competitive safety profile with mostly Grade 1 or 2 treatment-related adverse events, no significant off-target toxicity, and a low discontinuation rate.
- 80 mg once daily has been selected as the dose for potential Phase 3 development, with the next update for 1L EGFR PACC patients expected mid-2026.
Dec 5, 2025, 2:45 AM
ORIC Pharmaceuticals Provides Updates on ORIC-944 and ORIC-114 Programs, Financial Runway
ORIC
New Projects/Investments
Guidance Update
- ORIC Pharmaceuticals, a clinical-stage oncology company, is advancing two main programs: ORIC-944 for prostate cancer and ORIC-114 for lung cancer.
- For ORIC-944, recent data showed PSA 50 of 40% and PSA 90 of 20%, numerically higher than Pfizer's comparable data, along with a better safety profile. The company plans to initiate a Phase III study in the first half of 2026.
- ORIC-114, a selective brain penetrant EGFR exon 20 program, is highlighted for its CNS activity, which is crucial given that approximately one-third of patients present with baseline brain metastases. Key data updates are expected at ESMO Asia this week (as of December 3, 2025) across three indications, with frontline combination data with amivantamab anticipated in mid-2026.
- The company is well capitalized, with a cash runway extending into the second half of 2028, which is beyond the expected top-line Phase III data readout for ORIC-944.
Dec 3, 2025, 4:15 PM
ORIC Pharmaceuticals Discusses Clinical Program Progress and Financial Runway
ORIC
New Projects/Investments
Guidance Update
- ORIC Pharmaceuticals, a clinical-stage oncology company, is advancing two main programs: ORIC-944 for prostate cancer and ORIC-114 for lung cancer.
- For ORIC-944, a PRC2 inhibitor, the company reported a PSA 50 of 40% and a PSA 90 of 20%, which are numerically higher than Pfizer's mevrometostat, along with a better safety profile. A Phase 3 study for ORIC-944 is planned to commence in the first half of next year (2026).
- ORIC-114, a selective brain penetrant EGFR exon 20 program, will have a data update at ESMO Asia, with key differentiation points being its CNS activity and clean Kinome screens.
- The company is well-capitalized with a cash runway extending into the second half of 2028, supported by a $240 million financing round completed mid-year.
Dec 3, 2025, 4:15 PM
Quarterly earnings call transcripts for Oric Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more